Investigational drug · Phase 3
IBI311
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Thyroid Eye Disease, TED.
Phase 3Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
10
Any phase or sponsor naming "IBI311"
First trial start
2023
Oct 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI311", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
- Thyroid Eye Disease, TED
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI311" as an intervention, largest first.
- A Study of IBI311 in Subjects With Active Thyroid Eye DiseasePivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05795621 · 115 participants · Start Feb 14, 2023 · Primary completion Dec 20, 2023
Drug: IBI311; placebo · For: Thyroid Eye Disease
Sites: Shanghai, China
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseasePivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07113262 · 111 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 31, 2026
Drug: IBI311; Placebo · For: Thyroid Eye Disease
Sites: Shenyang, China
Shanghai Changzheng HospitalAcademic, hospital or other
NCT07152366 · 96 participants (planned) · Start Apr 15, 2025 · Primary completion May 31, 2027
Drug: IBI311; Glucocorticoids · For: Thyroid Associated Ophthalmopathies
Sites: Shanghai, China
- A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseasePivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06126783 · 91 participants · Start Oct 20, 2023 · Primary completion Sep 23, 2025
Drug: IBI311 · For: Thyroid Eye Disease, TED
Sites: Shanghai, China
Shanghai Changzheng HospitalAcademic, hospital or other
NCT07152340 · 64 participants (planned) · Start Apr 10, 2025 · Primary completion Apr 30, 2027
Drug: IBI311; Glucocorticoids · For: Thyroid Associated Ophthalmopathies
Sites: Changhua, China; Shanghai, China
- A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated OphthalmopathyPivotal-lookingCompleted
Peking University People's HospitalAcademic, hospital or other
NCT06269393 · 53 participants · Start Jan 1, 2024 · Primary completion Apr 3, 2025
Drug: Placebo; IBI311 · For: Thyroid Associated Ophthalmopathy
Sites: Beijing, China
- Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAORecruiting
Shanghai Changzheng HospitalAcademic, hospital or other
NCT07152392 · 50 participants (planned) · Start Apr 15, 2025 · Primary completion Jul 1, 2027
Drug: IBI311 · For: Thyroid Associated Ophthalmopathies
Sites: Shanghai, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06525506 · 38 participants · Start Sep 4, 2024 · Primary completion Jan 9, 2025
Drug: IBI311 (20 mg); IBI311 (3-20 mg) and 2 more · For: Thyroid Eye Disease
Sites: Suzhou, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05480579 · 28 participants · Start Aug 10, 2022 · Primary completion Nov 23, 2022
Drug: placebo; IBI311 and 6 more · For: Healthy
Sites: Shanghai, China
- Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Shanghai Changzheng HospitalAcademic, hospital or other
NCT06866548 · 7 participants (planned) · Start Mar 10, 2025 · Primary completion Nov 11, 2025
Drug: anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) · For: mCRPC
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of teprotumumab N01 (IBI311), an IGF-1R inhibitor, for thyroid eye disease patients who had failed glucocorticoids.
Zhao W, Li TY, Na Y, et al. · Int J Ophthalmol 2026
- Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zhang H, Zhang Z, Lu T, et al. · Drugs 2026
- Discordance between proptosis response and other clinical improvements at week 12 during teprotumumab N01 therapy for thyroid eye disease: a multicenter prospective registry study.
Gao W, Yan B, Hu J, et al. · BMC Ophthalmol 2026
- IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.
Zhang H, Sun J, Li Y, et al. · JAMA Ophthalmol 2025
Also in development for Thyroid Eye Disease
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- KHN939Phase 32 trials
Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
- lonigutamabPhase 21 trial
ACELYRIN Inc. · Thyroid Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.